Flow cytometric results of the TILs showed that aPD-L1 immunotherapy distinctly elevated the ratios of CD8+ T cells and CD8+IFN-γ+ T cells in the BMFsPD-L1-KO-mixed tumor xenografts as compared with the control group (Figures 3E–H). The gene discussed is CD8A; the disease is neoplasm.